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Abstract:
Background: Observational studies comparing ticagrelor and prasugrel in 
this setting have yielded contradictory results but often do not consider 
differential censoring (e.g., for treatment switching or insurance 
disenrollment)or confounding by time dependent factors. 
Objective: Our objective was to conduct a comparative effectiveness and 
safety analysis of ticagrelor and prasugrel in patients who underwent PCI 
after being hospitalized for an acute coronary syndrome. 
Methods: This study used the Optum’s de-identified Clinformatics® Data 
Mart Database and included patients aged 18 years or older with an 
index hospital admission between May 2012 and December 2015, a 
diagnosis of acute coronary syndrome managed with percutaneous 
coronary intervention, and treatment with either ticagrelor or prasugrel. 
The primary composite outcome was defined as the first occurrence all-
cause death, myocardial infarction, or ischemic stroke. The secondary 
composite outcome included the first occurrence of gastrointestinal 
bleed, intracranial hemorrhage, or other major bleeds requiring 
hospitalization. Weighted Cox proportional hazard models and robust 
variance estimation were implemented to adjust for baseline 
comorbidities, time-varying exposure, time-dependent confounders, and 
differential censoring. 




ticagrelor and 4,456 patients initiated on prasugrel following PCI. 
Patients initiated on ticagrelor were 10% more likely to have eligibility 
disenrollment (Ticagrelor: 57%, Prasugrel: 47%, P<.01) and 7 
percentage-points more likely to switch medication (Ticagrelor: 35%, 
Prasugrel: 28%, P<.01). After adjusting for multiple factors, including 
time-varying exposure, and censoring imbalance, ticagrelor use was 
associated with a higher risk of all-cause death, MI, or stroke when 
compared to prasugrel (HR: 1.33; 95%CI: 1.04-1.68). Similarly, 
ticagrelor was associated with a higher risk in bleeding events when 
compared with prasugrel (HR: 1.61; 95%CI: 1.19-2.17). 
Conclusion: When compared with ticagrelor, prasugrel use following PCI 
for ACS was associated with a lower risk of death, MI, or stroke. as well 
as with a reduced risk of major bleeding. 
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Background: Observational studies comparing ticagrelor and prasugrel in this setting 
have yielded contradictory results but often do not consider differential censoring (e.g., 
for treatment switching or insurance disenrollment)or confounding by time dependent 
factors.
Objective: Our objective was to conduct a comparative effectiveness and safety 
analysis of ticagrelor and prasugrel in patients who underwent PCI after being 
hospitalized for an acute coronary syndrome.
Methods: This study used the Optum’s de-identified Clinformatics® Data Mart 
Database and included patients aged 18 years or older with an index hospital admission 
between May 2012 and December 2015, a diagnosis of acute coronary syndrome 
managed with percutaneous coronary intervention, and treatment with either ticagrelor 
or prasugrel. The primary composite outcome was defined as the first occurrence all-
cause death, myocardial infarction, or ischemic stroke. The secondary composite 
outcome included the first occurrence of gastrointestinal bleed, intracranial hemorrhage, 
or other major bleeds requiring hospitalization. Weighted Cox proportional hazard 
models and robust variance estimation were implemented to adjust for baseline 
comorbidities, time-varying exposure, time-dependent confounders, and differential 
censoring. 
Results: Included in the analysis were 2,559 patients initiated on ticagrelor and 4,456 
patients initiated on prasugrel following PCI. Patients initiated on ticagrelor were 10% 
more likely to have eligibility disenrollment (Ticagrelor: 57%, Prasugrel: 47%, P<.01) 
and 7 percentage-points more likely to switch medication (Ticagrelor: 35%, Prasugrel: 
































































28%, P<.01). After adjusting for multiple factors, including time-varying exposure, and 
censoring imbalance, ticagrelor use was associated with a higher risk of all-cause death, 
MI, or stroke when compared to prasugrel (HR: 1.33; 95%CI: 1.04-1.68). Similarly, 
ticagrelor was associated with a higher risk in bleeding events when compared with 
prasugrel (HR: 1.61; 95%CI: 1.19-2.17).
Conclusion: When compared with ticagrelor, prasugrel use following PCI for ACS 
was associated with a lower risk of death, MI, or stroke. as well as with a reduced risk 
of major bleeding. 

































































Dual antiplatelet therapy (DAPT), with aspirin and a P2Y12 agent, reduces the risk of 
subsequent ischemic events and is a mainstay in treatment in patients with acute 
coronary syndrome undergoing percutaneous coronary intervention (PCI).1–3  In the 
TRITON-TIMI-38 trial, less ischemia but more bleeding occurred in the prasugrel 
than clopidogrel group. In contrast, in the PLATO trial comparing ticagrelor and 
clopidogrel, both agents reduce CV death, MI, and stroke by the same magnitude and 
both agent increase non-CABG TIMI major bleeding by the same magnitude..  The 
Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary 
Treatment (ISAR-REACT) 5 trial, a randomized, open-label study evaluating 
ticagrelor versus prasugrel in patients with acute coronary syndrome (ACS) in whom 
an invasive evaluation was planned, found that patients receiving ticagrelor had a 
significantly higher incidence of death, myocardial infarction, or stroke but similar 
rates of major bleeding over 1 year of follow up.4 Observational studies comparing 
ticagrelor and prasugrel in this setting have yielded contradictory results, 5–9 but have 
not taken into account the possibility of differential censoring (e.g., for treatment 
switching or insurance disenrollment), nor of confounding by time dependent factors, 
both of which can affect study outcomes.10 
We conducted a comparative effectiveness and safety analysis of ticagrelor and 
prasugrel in patients who underwent PCI for an acute coronary syndrome. We 
implemented marginal structural models and employed inverse probability censoring 
weighting to adjust for post-treatment selection bias caused by imbalance in treatment 
































































switching and insurance disenrollment between comparison groups. We hypothesized 
that after adequate adjustment for confounding and selection bias, a real-world 
comparative effectiveness and safety study would yield results similar to those observed 
in the ISAR-REACT 5 trial. 
METHODS
Data Source
We utilized Optum’s de-identified Clinformatics® Data Mart Database (Optum Inc., 
Eden Prairie, MN), a large, nationwide, managed care, administrative claims dataset 
comprised of longitudinal medical billing information in the United States. Insurance 
claims for all pharmacy, inpatient, and outpatient services are included for the enrolled 
13 million yearly-members.11 This project was designated as “research not involving 
human subjects” by the University of Rhode Island Institutional Review Board, as all 
data were de-identified prior to analyses.
Study Cohort
Patients aged 18 years and older hospitalized between May 2012 and September 2015 
with a diagnosis of ACS managed with PCI and treated with either prasugrel or 
ticagrelor were included. This period was selected to align with the FDA approval of 
ticagrelor in July 2011, allowing for delayed acceptance into insurance formularies. 
ACS was identified using the International Classification of Diseases, Ninth Revision, 
Clinical Modification (ICD-9-CM) codes (ICD-9-CM: 410.x [acute myocardial 
infarction] and 411.x[other acute and subacute forms of ischemic heart disease]).12 
































































PCI was identified by ICD-9-CM and Current Procedural Terminology (CPT-4) 
procedure codes (ICD‐9‐CM: 00.66, 36.01, 36.02, 36.05, 36.06, 36.07, and 36.09; 
CPT‐4: 92980, 92981, 92982, 92984, 92920, 92921, 92924, 92925, 92928, 92929, 
92933, 92934, 92937, 92938, 92941, 92943, 92944, 92973) occurring during the index 
hospitalization.9 At least one pharmacy prescription claim for either ticagrelor or 
prasugrel within 14 days of discharge was required.9 Patients with prior dispensing of 
ticagrelor or prasugrel, history of stroke, fibrinolytic therapy within one day of 
hospitalization, prior dispensing of oral anticoagulants, or dispensing of strong 
Cytochrome P-450 3A inhibitors/inducers identified during the baseline period were 
excluded.4,13 Additionally, patients with claims for more than one or any non-study 
antiplatelet agents during the 14-day initiation window were excluded.
Outcomes Assessments
The primary composite outcome was defined as the first occurrence of one of any of the 
following: all-cause death, myocardial infarction, or ischemic stroke. All-cause death 
was identified utilizing the Social Security Administration’s Death Master File. Since 
only the month and year of death were included in these data, a day of death was 
randomly assigned within each month for death events occurring after hospital 
discharge. Myocardial infarction and stroke were identified by ICD-9-CM diagnosis 
codes (MI: 410-412 [excluding 410.x2]; Stroke: 430-434, 436) occurring during 
hospitalization.14,15 The secondary composite outcome was defined as the first 
occurrence of one of the following: gastrointestinal bleed, intracranial hemorrhage, or 
other major bleeding requiring hospitalization.16 Patients were followed from index 
































































hospitalization discharge until primary endpoint occurrence, loss of insurance eligibility, 
or for 365 days; whichever occurred first. 
Censoring Assessment
Censoring events included insurance disenrollment, treatment switching, treatment 
discontinuation, or end of data window on September 30, 2015. Insurance disenrollment 
was identified by eligibility end or a gap of 30 days or more in insurance enrollment. 
Treatment switching was classified by the discontinuation of the initially prescribed 
antiplatelet therapy and initiation of an alternative medication, as identified via 
prescription pharmacy claims. Patients who switched to ticagrelor or prasugrel were not 
censored at switch date consistent with the time-varying exposure analysis described 
below. However, patients that switched to clopidogrel were censored. Therapy 
discontinuation was defined as a greater than 45 days of gap between prescription end 
of supply and refill. Since treatment duration of 6 to 12 months is recommended in this 
clinical setting, gaps greater than 45 days occurring after 6-months of follow-up were 
not evaluated.17 
Covariate Assessment
Baseline covariates assessed during the 6-month baseline window included: age, sex, 
hypertension, tobacco use, hyperlipidemia, major bleeding, peripheral vascular disease, 
chronic kidney disease, dialysis, anemia, chronic obstructive pulmonary disease, 
previous percutaneous transluminal angioplasty, previous coronary artery bypass graft, 
congestive heart failure, atrial fibrillation, and beta-blocker, diuretic, statin, proton-
































































pump inhibitor, or diabetes medication use.  These are time-fixed potential confounding 
factors specified by previous studies. 17,18 A time variable was generated for each 
person-time interval when the exposure was assessed. Angina, prior interval treatment, 
and interval time were included as time-dependent covariates assessed during each 
month of follow-up.
Statistical Analysis
Categorical variables are presented as frequencies (%) and compared using chi-square 
tests. Continuous variables are presented as mean ± standard deviation (SD) and were 
compared between two drug groups using student t-test. Marginal-structural models 
(MSM) were fit using inverse probability weights (IPW) to adjust for confounding with 
time-dependent variables.19,20 Possible violations of positivity and misspecification 
were assessed in all models by inspecting the estimated stabilized weight distribution to 
check for extreme values and to confirm that the mean was approximately equal to 
one.21 The proportional hazards assumption was assessed graphically by examining the 
IPW log cumulative hazard function estimates to ensure that the hazard curves remained 
parallel over time.
Time-Dependent Exposure (TD)
Weighted Cox proportional hazard models and robust variance estimation were 
implemented to adjust for baseline and time-dependent confounders.22,23  The robust 
variance estimator was required to account for the additional variability introduced by 
estimating the IPWs. The time-dependent weights were constructed to adjust for fixed 
































































baseline and time-varying confounding factors.  Exposure was assessed at monthly 
intervals of prescription dispensing for each patient following initial assignment and 
continued until loss of eligibility, switching to clopidogrel, treatment discontinuation, 
event occurrence, or study end. Weights for each person-time interval were created by 
the ratio of the probability that each patient received their observed treatment 
conditional on time, and past treatment divided by the probability that the patient 
received the observed treatment given time, past treatment, baseline covariates, and 
prognostic (time-dependent) factors.24 
Censoring Weighting (CW)
The censor-weighting accounted for possible informative censoring (e.g., insurance 
disenrollment) due to measured confounding factors. These weights were estimated as 
the ratio of the probability of remaining enrolled in the insurance program for 12-months 
following index hospitalization given time of the exposure assessed, prior treatment 
divided by the conditional probability of remaining enrolled given time, prior treatment, 
baseline variables, and time-dependent confounding factors.24,25 The time-dependent 
exposure and censoring weights were multiplied together for each person-time interval 
of follow-up for each patient.
Sensitivity Analyses
Intention-To-Treat Analysis (ITT)
A conventional ITT analysis was conducted to better enable comparison with the 
approaches used in previously published observational studies. Patients were censored 
































































if loss of follow-up due to insurance disenrollment but were not censored based on 
treatment discontinuation, adherence, or switching. The IPWs were derived by a ratio 
of the marginal probability of exposure and the probability of exposure given baseline 
covariates.26 The weights were used to create a pseudopopulation in which the measured 
covariates and treatment assignment were independent of each other. No adjustments 
were made for time-dependent confounding factors. We hypothesized that not adjusting 
for dropout or switching imbalances between exposure groups would bias results toward 
the null.
Clopidogrel Naïve Population
To determine if clopidogrel exposure during baseline period was associated with the 
study outcomes, we narrowed the population to antiplatelet-naïve patients by 
excluding those with clopidogrel exposure during the baseline period. While the 
ISAR-REACT 5 trial did not exclude patients with a history of clopidogrel use, we 




There were 91,682 individuals admitted with an ACS who underwent PCI during the 
study period. Of these, 71,287 had 6-months of insurance eligibility prior to index 
hospitalization. After applying the exclusion criteria, there were 2,559 initiated on 
































































ticagrelor and 4,456 initiated on prasugrel following PCI who were included in this 
analysis (Figure 1).
The ticagrelor group had significantly higher incidences of comorbidities at baseline as 
compared with those who initiated prasugrel (Table 1). The ticagrelor group was older, 
had higher rates of hypertension, chronic kidney disease, anemia, chronic obstructive 
pulmonary disease, congestive heart failure, and atrial fibrillation. Patients initiated on 
ticagrelor were 10% higher on eligibility disenrollment and 7% higher on medication 
switching (absolute differences in Table 2). The ticagrelor group had a 2 percentage-
point higher use of clopidogrel during baseline compared to the prasugrel group 
(absolute differences in Table 2). Treatment discontinuation was balanced between 
groups. 
Comparative Effectiveness Results
In the unadjusted analysis, the composite outcome, death, myocardial infarction, or 
ischemic stroke, occurred numerically more often in the ticagrelor group (Table 3). The 
rates of gastrointestinal bleeding, intracranial hemorrhage, and other major bleeding 
requiring hospitalization were also numerically greater in the ticagrelor group, however 
neither difference in composite endpoint rates was statistically significant. After 
adjusting for multiple confounding factors, time-varying exposure, and censoring 
imbalance, ticagrelor was associated with a higher risk of the composite all-cause death, 
MI, or stroke, when compared to prasugrel (HR: 1.33; 95%CI: 1.04-1.68; p=0.02) 
(Table 4). Similarly, ticagrelor was also associated with a higher risk of bleeding events 
































































(HR: 1.61; 95%CI: 1.19-2.17; p<0.01). Figures 2 and 3 show the survival curves for 
outcomes in the IPW estimated pseudopopulation.
Sensitivity Analysis Results
Intention-To-Treat Analysis (ITT)
The conventional ITT analysis that did not adjust for the disenrollment or switching 
imbalance between groups derived estimates in the opposite direction. With the ITT 
approach, ticagrelor was associated with numerically fewer all-cause death, MI, and 
stroke events (HR: 0.78; 95%CI: 0.58-1.06; p=0.11) and numerically fewer bleeding 
events (HR: 0.84; 95%CI: 0.58-1.20, p=0.33), but these differences were non-
significant. 
Clopidogrel Naïve Population
Results for the sensitivity analyses that excluded patients dispensed clopidogrel during 
baseline were similar to those from the ISAR-REACT 5 study population, where prior 
clopidogrel use was allowed. The TD-CW method for ischemic (HR: 1.28; 95%CI: 
0.99-1.66; p=0.06) and bleeding (HR: 1.63; 95%CI: 1.19-2.23, p<0.01) composite 
outcomes remained consistent. Similarly, ITT results for the primary composite 
outcome (HR: 0.81; 95%CI: 0.59-1.11; p=0.19) and secondary composite outcome 
(HR: 1.05; 95%CI: 0.73-1.51; p=0.79) were similar in direction although not 
significantly different.
DISCUSSION
































































In this real-world study using a national claims dataset we compared the incidence of 
composite ischemic and bleeding events between hospitalized patients prescribed 
ticagrelor or prasugrel after PCI for an ACS. Two analytic methods were applied. In 
TD-CW analyses with Marginal Structural Models, ticagrelor was associated with a 33% 
increased hazard of all-cause death, MI, or stroke, as well as a 61% greater hazard for 
ICH, GI bleed, or major hemorrhage. However, in traditional ITT analyses there were 
no significant differences in ischemic or bleeding outcomes between treatments. 
Our findings from the TD-CW analysis were consistent with the ISAR-REACT 5 trial 
which found that prasugrel was associated with a lower risk of ischemic and bleeding 
events in patients treated for ACS. While treatment guidelines recommend prasugrel or 
ticagrelor equally following PCI, many clinical and non-clinical factors can influence 
treatment selection, potentially explaining the observed imbalances in disenrollment 
and antiplatelet switching.17,27 While observational studies can adjust for baseline 
imbalances between groups, post-exposure events are not often evaluated. We 
implemented a time-dependent exposure and censor weighted model to adjust for the 
censoring imbalances identified in Table 2. In order to replicate/mimic findings from 
the RCT, we need to conduct a study in which adherence is similar. To do this, we need 
to account for time-varying confounding and censoring to get an accurate ‘on treatment’ 
effect. Thus, we applied methods for time-dependent confounding, drug switching and 
discontinuation to account for differences in adherence/discontinuation between the 
































































real-world data and RCT. Accounting for these factors within the observational cohort 
resulted in dropout and treatment switching rates that were similar to the ISAR-REACT 
5 trial. The results from this analysis were in the same direction as the trial results.
The observational literature regarding outcomes of antiplatelet use have conflicting 
results.5–9,18,28 Differences in how study designs address variability in follow-up time, 
inclusion and exclusion criteria, approaches for addressing covariates may lead to 
divergent conclusions.  Using a conventional ITT analytic approach that fails to address 
censoring events that are imbalanced between treatment groups, and differential 
censoring can lead to different interpretations of the estimates. Dawwas et al. evaluated 
the comparative effectiveness and safety of ticagrelor versus prasugrel in patients with 
ACS.28 Their results indicated that ticagrelor was associated with a decreased risk of 
recurrent nonfatal CVD events (HR: 0.80, 95%CI: 0.70-0.92), and major bleeding 
events (HR: 0.54, 95%CI: 0.41-0.70). In contrast, some observational studies suggested 
a benefit with prasugrel over ticagrelor. For example, Larmore et al. found that major 
adverse cardiovascular and major bleeding events were lower at 30-days in the 
prasugrel-treated group when compared to the ticagrelor-treated group.29 However, 
most observational studies found no significant difference in the incidence of adverse 
cardiovascular and bleeding events when comparing these agents.7-11 Our ITT 
sensitivity analysis provided results that were consistent with recent observational 
studies evaluating these agents and that were contrary to the ISAR-REACT 5 trial. 
Ignoring differential post-assignment imbalances between exposure groups produced 
results in the opposite direction. The variability of results in observational studies may 
































































be attributed to different study populations, and most likely unaddressed post-treatment 
selection bias as none of these studies assessed or compared medication switching or 
disenrollment rates in comparison groups during study follow-up.
While there was a statistically significant 2% higher clopidogrel exposure rate in the 
ticagrelor group during the baseline period , narrowing the population to antiplatelet-
naïve patients by excluding those with prior clopidogrel exposure produced similar 
results with a slight loss in power. This suggests that clopidogrel use at baseline period 
did not impact the estimated treatment effect.
The key difference between the analysis methods lies in adjusting for confounding that 
results in incomplete adherence to the assigned treatment. It has been noted in clinical 
trials that loss to follow-up may be affected by clinical or demographical factors 
occurring after randomization. Our results further confirmed that the imbalance of 
medication switching or insurance disenrollment between exposures could bias the 
results. Adjusting for post-assignment factors can help improve the precision of effect 
estimates. After adjusting for time-varying confounding and treatment in the TD-CW 
analysis, our findings were consistent with the ISAR-REACT 5 trial where the post-
treatment selection bias was addressed. 
LIMITATIONS
First, this study is based on claims data and could be biased by unmeasured confounding 
factors (e.g., over-the-counter medications, antiplatelet loading-dose, or other details of 
































































inpatient procedures). Second, a substantial number of patients were excluded for not 
having an outpatient dispensing of the study treatment within 14-days of index PCI. 
Subsequent analysis of the 27,049 patients excluded indicated that the majority did not 
have pharmacy dispensings of the study agents. The 14-day window captured >83% of 
the patients with pharmacy dispensing of the study treatments in the database. We 
presume that most of the patients with no dispensings of antiplatelet agents following 
PCI were treated and recorded using a different payment system. Increasing this window 
to 30 and 90 days did not greatly improve the number of patients identified. However, 
these effects are thought to be non-differential as we are comparing two drugs from the 
same drug class. Third sub-codes differentiating between types of myocardial events 
such as STEMI or NSTEMI were not reliably utilized in the data to differentiate as 
outcomes. Fourth, our results pertain to patients enrolled in a managed care plan and 
may not be generalizable to other populations. Additionally, the death file included 
within this dataset is the Social Security Administration Death Master file. Since 2013 
it was no longer mandatory for states to report death events to the Social Security 
Administration. As such, death events are expected to be non-differentially 
underreported.30  Lastly, there are several key assumptions that must be made to obtain 
correct causal inferences from the time-varying approaches. We assumed that the 
measured covariates, including baseline and time-varying factors, were sufficient to 
adjust for both confounding and post-treatment selection bias. This assumption is not 
testable in retrospective observational studies; however, we relied on comprehensive 
literature review and clinical expertise to bolster this assumption. While many of the 
covariates were selected to mimic previous clinical trials, information regarding 
































































gastrointestinal disorders or abnormalities may be factors of interest for future studies. 
We also assumed that the models implemented were suitably specified, including the 
MSM comparing average treatment effects conditional on time-varying exposure, 
baseline covariates, and time-varying confounders. While these assumptions are not 
testable, we fit the same covariates in all models to make these results comparable. 
CONCLUSION
After adjusting for confounding factors, time-varying exposure, and censoring 
imbalance using marginal structural models with TD-CW, results from our 
observational data mirrored those from a contemporary randomized controlled trial 
asking the same question; application of such statistical methods may augment future 
comparative effectiveness and safety analyses using observational data.
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Exclusions (N = 21,346):
1. PCI-ACS Discharge Prior to 
01March2012: N = 14,150
2. Fibrinolysis within 24hr of 
hospitalization: N = 347
3. Anticoagulant use at baseline: 
N = 2,177
4. CYP-450 inducer or inhibitor 
(strong): N = 4,451
5. History of intracranial 
hemorrhage: N = 89
6. Prior exposure to ticagrelor or 












No antiplatelet dispensing 





































































Table 1. Baseline Characteristics by Initial Exposure
 Ticagrelor (%) Prasugrel (%)
Characteristics n = 2,559 n = 4,456 P
Age (±SD) 65.3 ±11.7 59.8 ±10.2 <0.01
Female 820 (31) 968 (21) <0.01
Tobacco Use 633 (24) 1,195 (26) 0.04
Hypertension 2,041 (77) 3,233 (71) <0.01
Hyperlipidemia 1,916 (73) 3,338 (73) 0.64
Carotid Artery Stenosis 126 (5) 143 (3) <0.01
Chronic Kidney Disease 231 (9) 282 (6) <0.01
Anemia 277 (10) 308 (7) <0.01
Chronic Obstructive
Pulmonary Disease
386 (15) 503 (11) <0.01
Asthma 133 (5) 204 (4) 0.27
Percutaneous Transluminal
Coronary Angioplasty
271 (10) 410 (9) 0.07
Coronary Artery Bypass
Graft
136 (5) 199 (4) 0.12
Congestive Heart Failure 514 (19) 727 (16) <0.01




1,027 (39) 1,605 (35) <0.01
Beta-Blocker 778 (29) 1,105 (24) <0.01
Diuretic 425 (16) 561 (12) <0.01
Statin 999 (38) 1,581 (35) <0.01
Diabetic Medication 654 (25) 1,058 (23) 0.12
Proton-Pump Inhibitor 464 (18) 646 (14) <0.01
Baseline Clopidogrel Exposure 210 (8) 278 (6) <0.01

































































Table 2. Censoring Frequencies by Initial Exposure
 Ticagrelor (%) Prasugrel (%)





        Mean (±SD) 278 (± 113)            294 (± 109)
         Median (IQR) 365 (190-365) 365 (231-365)
Insurance Disenrollment 
During Follow-up
1493 (57) 2139 (47) <0.01
Medication Switch 931 (35) 1278 (28) <0.01
Switch to Clopidogrel 815 (88) 1273 (100)
Treatment Discontinuation 230 (9) 439 (10) 0.22






































































n = 4,566 P 
value
Primary Outcomes
All-cause Death 33 (1.3) 60 (1.3) 0.82
Myocardial Infarction 109 (4.1) 150 (3.3) 0.06
Stroke 29 (1.1) 24 (0.5) <0.01
Death, MI, Stroke 119 (4.5) 172 (3.8) 0.12
     Rate per 100 person-years 7.1 per 100 person-years 5.3 per 100 person-years
Secondary Outcomes    
Gastrointestinal Bleed 63 (2.4) 84 (1.8) 0.11
Other Major Bleed 29 (1.1) 41 (0.9) 0.40
Intracranial Hemorrhage 11 (0.4) 17 (0.4) 0.77
Bleeding Outcomes 72 (2.7) 98 (2.1) 0.12
     Rate per 100 person-years 4.7 per 100 person-years 3.3 per 100 person-years

































































Table 4. Adjusted Hazard Ratios for Ischemic and Bleeding Events by Analysis 
Methods
Time-Dependent Censor-Weighted (TD-CW) HR 95% Cl P
All-cause death, MI, Stroke 1.33 (1.04 - 1.69) 0.02
ICH, GI Bleed, Major Hemorrhage 1.61 (1.19 - 2.17) <0.01
Intention-to-Treat (ITT)
All-cause death, MI, Stroke 0.78 (0.58 - 1.06) 0.11
ICH, GI Bleed, Major Hemorrhage 0.84 (0.58 - 1.20) 0.33
Clopidogrel-Naive TD-CW
All-cause death, MI, Stroke 1.28 (0.99 - 1.66) 0.06
ICH, GI Bleed, Major Hemorrhage 1.63 (1.19 - 2.23) <0.01
Clopidogrel-Naive ITT
All-cause death, MI, Stroke 0.81 (0.59 - 1.11) 0.19
ICH, GI Bleed, Major Hemorrhage 1.05 (0.73 - 1.51) 0.79
Note: Myocardial infarction (MI), intracranial hemorrhage (ICH), gastrointestinal 
bleed (GI bleed)

































































Figure 2. Estimated Survival Curve for death, myocardial infarction (MI), or stroke in 
weighted pseudopopulation


































































































Figure 3. Estimated survival curve for gastrointestinal (GI) bleed, intracranial hemorrhage (ICH), 
or other major bleed requiring hospitalization in weighted pseudopopulation


































































































Appendix Table 1. Baseline Covariates IDC-9 Codes:
Characteristic ICD-9 Codes for Baseline Characteristics 
(decimal points removed)
Percutaneous Coronary Intervention  3601 3602 3605 3606 3607 3609 0066 92980 
    92981 92982 92984 92920 92921 92924 
92925 92928
   92933 92934 92937 92938 92941 92943 
92944 92973 
Acute Coronary Syndrome 410 411
Fibrinolysis 37201 37211 37212 37213 37214 37195 92977 
9910
Tobacco 3051 V1582
Hypertension 4011 4019 4010 40200 40201 40210 40211 
40290 40291
   4030 40300 40301 4031 40310 40311 4039 
40390 40391
   4040 40400 40401 40402 40403 4041 40410 
40411 40412
   40413 4049 40490 40491 40492 40493 40501 
40509 40511
   40519 40591 40599 4372 
Hyperlipidemia 2720 2721 2722 2723 2724
Diabetes 24900 25000 25001 7902 79021 79022 79029 
7915 7916
   V4585 V5391 V6546 24901 24910 24911 
24920 24921 24930
   24931 24940 24941 24950 24951 24960 
24961 24970 24971
   24980 24981 24990 24991 25002 25003 
25010 25011 25012 
   25013 25020 25021 25022 25023 25030 
25031 25032 25033
   25040 25041 25042 25043 25050 25051 
25052 25053 25060 
   25061 25062 25063 25070 25071 25072 
25073 25080 25081 
   25082 25083 25090 25091 25092 25093
Carotid Artery Stenosis 43310 43311
Peripheral Vascular Disease 4400 4401 4402 44020 44021 44022 44023 
44029 4404
   4408 4409 4439 5570 5571 5579
End Stage Renal Disease 5856
Chronic Kidney Disease 585 5851 5852 5853 5854 5855 5859 

































































Anemia 2800 2801 2808 2809 2810 2811 2812 2813 
2814
    2818 2819 2820 2821 2822 2823 2824 28240 
28243
    28244 28245 28246 28247 28249 2827 2828 
2829 2830
    2831 28310 28311 28319 2832 2839 2840 
28401 28409
    2841 28411 28412 28419 2842 2848 28481 
28489 2849
    2850 28521 28522 28529 2858 2859
Chronic Obstructive Pulmonary Disease 490 4910 4911 4912 49120 49121 49122 4918 
4919 4920
    4928 494 4940 4941 496
Asthma 49300 49301 49302 49310 49311 49312 49320 
49321 49322
    49381 49382 49390 49391 49392
Percutaneous Transluminal Coronary 
Angioplasty
V4582
Coronary Artery Bypass Graft V4581
Congestive Heart Failure 428 4280 4281 4282 42820 42821 42822 42823 
4283 42830
   42831 42832 42833 4284 42840 42841 42842 
42843 4289
Atrial Fibrillation 42731
Intracranial hemorrhage 431 430
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Response: We sincerely appreciate the reviewer’ constructive comments and editor’s 
consideration. We will address all comments and resubmit the revised manuscript and 
point-to-point responses. 
Reviewer(s)' Comments to Author:
Reviewer: 1
Comments to the Author
This manuscript is a real-world comparative effectiveness study of prasugrel and ticagrelor for 
ACS with PCI.
1. Abstract: Please include a brief Background section.
Response: Added a background section to abstract 
2. Page 8: Methods, Covariate Assessment - why wasn't STEMI, NSTEMI or unstable angina 
NOT included in the analysis? It is a predictor of outcome. If you were not able to discern from 
the database, describe in the limitations.
Response: Sub-codes differentiating between types of myocardial events such as STEMI 
or NSTEMI are not reliably utilized to differentiate as outcomes.1
3. Limitations Page 16: Exclusion Criteria/Figure 1: I calculated that 38% of patients in the 
database were excluded for lack of 14-day dispensing which is capturing 72% not 83%. Please 
reconcile.
































































Response: Updated the language in the limitations section to make clearer. The 14-day 
window identified 83% of the patients within the database that had a pharmacy 
dispensing for the study treatment following PCI. During post-hoc analysis of the 27,049 
patients excluded, only 10% had prescription dispensing for study agents at anytime 
following PCI, with 3-5% having dispensings within 15 to 90-days. Thus, using the 14-day 
window, we identified most of the patients with evidence of initiation of study treatment 
following PCI. Most of the 27,049 excluded did not have claims for the therapies of 
interest. 
4. Figure 1: Where are those patients with PRIOR dispensing (page 7 line 15) in your figure?
Response: There were 70, 27, and 35 patients in prasugrel, ticagrelor, and clopidogrel 
groups that had prior dispensings to either prasugrel or ticagrelor respectively. These 
patients were grouped with prior antiplatelet exclusion. Figure 1 has been updated to 
reflect this.
5. Exclusion Criteria/Figure 1: What were the strong CYP3A inducers and inhibitors prescribed? 
Figure 1 indicates 5-10% of patients were excluded. In practice those amount to clarithromycin 
and rifampin. Neither of which in my experience are prescribed often. Please re-evaluate these 
medications. Or did you mean moderate and strong?
Response: Patients taking strong CYP inducers or inhibitors were excluded (any CYP 
Isoenzyme, not just 3A4). A list is provided at the end of this document. The language 
was fixed in the manuscript.
6. Table 1: Please include whether the patient had STEMI, NSTEMI or unstable angina.
Response: STEMI and NSTEMI cannot be precisely assessed in the claims data. 
Sentence added in the limitations section.. No evidence has shown that STEMI, NSTEMI, 
or unstable angina significantly related to prescribing of t o study drugs.
7. Table 3: You need to either define Composite Outcomes or change the labels. Consider 
redefining primary outcome as primary efficacy outcomes and secondary as secondary bleeding 
outcomes. As is, you have two labels: Composite Outcome that have different meanings.
Response: Edited table 3 so that outcomes are clearer.
8. All patients were followed for various times, correct? What was the median for each group? 
Add to the results. More importantly, why aren't the results presented in annualized events or 
per patient per some time period? (Tables 2 and 3) If it is taken into consideration in the 
analysis, please explain it more clearly in the methods.
Response: FU time is Added to table 2. Results as rate per person-time added to table 3.
































































9. Figures 2 and 3 are not mentioned in the manuscript. Should they be? If not, delete.
Response: Sentence added at the end of the results section. 
Reviewer: 2
Comments to the Author
General comments to the authors:
I would like to congratulate the authors on an interesting and timely manuscript. Overall, the 
paper is well written with some specific revisions discussed below. Here are some general 
comments on the manuscript:
1.      The major issue with the manuscript is a thorough explanation of how and why their 
specific time exposure and censoring weighting methods impact the data findings. The data 
presented shows that it changes the interpretation of the data, but the reader does not gain an 
understanding of why and how the data changed.  I would highly recommend more explanation 
of these methods, possible providing an example of how and why these methods change the 
findings in the introduction or discussion.
Response: Thank you for your important suggestion. We have added a sentence at the 
end of the second paragraph of the discussion section: “In order to replicate/mimic 
findings from the RCT, we need to conduct a study in which adherence is similar. To do 
this, we need to account for time-varying confounding and censoring to get an accurate 
‘on treatment’ effect. Thus, we applied methods to account for time-dependent 
confounding, drug switching and discontinuation to account for differences in 
adherence/discontinuation between the real-world data and RCT. Accounting for these 
factors within the observational cohort resulted in dropout and treatment switching rates 
that were similar to the ISAR-REACT 5 trial. The final results from this analysis were in 
the same direction as the trial results We also have explained in detail  the time-
dependent exposure and censoring weighting in the methods section. 
2.      Suggest changing the title to use “an observational study” instead of “a real-world data 
study”. Although the use of real-world seems to be popular lately, especially by pharmaceutical 
manufacturers, these are plain and simply observational studies.
Response: changed to “Real-world data study”.
3.      Throughout the manuscript the “12” in P2Y12 should be subscript. Also, the correct term is 
acute coronary syndrome and not acute coronary syndromes.  It is a single syndrome.  It 
appears in both forms throughout the manuscript.
Response: Fixed both typos. 
Specific comments for the authors:
































































Page 5, lines 15-19:    The statement about there not being a difference in bleeding in the 
PLATO trial is misleading. In practically all trials of P2Y12 inhibitors, the consistent definition of 
major bleeding is non-CABG TIMI major bleeding. This is what was used in TRITON-TIMI 38 
and CURE. In PLATO the definition was manipulated to include all TIMI major bleeds. Since 
approximately 75% of patients going to CABG surgery have a major bleed, this dilutes the 
difference between the arms.  When the consistent definition of non-CABG TIMI major bleeding 
is evaluated in PLATO, there is a significant increase compared to clopidogrel, with the same 
absolute increase as seen in TRITON.  Both agents increase this consistent definition of major 
bleeding. Therefore, it would be appropriate to state that both agents reduce CV death, MI, and 
stroke by the same magnitude and both agent increase non-CABG TIMI major bleeding by the 
same magnitude.
Response: Changed the statement to “both agents reduce CV death, MI, and stroke by 
the same magnitude and both agents increase non-CABG TIMI major bleeding by the 
same magnitude.”
Page 6, top:   So there was no equipoise in the evaluation of your data?  Then did you do a one-
tailed statistical analysis? 
Response: In this observational study, there was no equipoise like there was in the RCT. 
Since as physicians perceived that Ticagrelor was superior to Prasugrel, there was 
confounding by indication which we attempted to account for through proper analysis.  
before ISAR-REACT 5 trial. 2–6The final estimates are adjusted HR, which is similar as the 
one-tailed statistical analysis that shows the higher risk in one agent. 
Page 7, lines 10-13:    It would seem more appropriate to include pharmacy claims within 30 or 
45 days of discharge instead of 14 days. With many hospitals using meds-to-beds programs, 
the first month of medication is often provided to patients before they leave the hospital, and 
therefore, would not be captured in your data. Both ticagrelor and prausgrel also often gave the 
first month of medication for free, which would also have limited your ability to capture these 
patients. One of the main strengths of a comparative effectiveness study is the ability to capture 
larger numbers of patients than a randomized controlled trial.  By limiting your pharmacy claims 
window, you reduce the power and impact of your results. You do mention this is your 
limitations, but seems to be an easy fix. It is someone confusing in your limitations discussion 
where you lose almost 25% of the study population because of this exclusion, but then state by 
changing the pharmacy claims date you did not gain many patients?  These two statements do 
not seem to be consistent unless most of the patients did not have any claim until beyond 90 
days.
Response: We sincerely appreciate reviewer’s important suggestion. We actually have 
examined 30 days and 45 days and didn’t observe a substantial increase in sample size. 
Also, patients may have events within 30 days or 45 days. The 14-day window identified 
83% of the patients within the database that had a pharmacy dispensing for the study 
treatment following PCI. During post-hoc analysis of the 27,049 patients excluded, only 
about 10% had prescription dispensing for study agents at any time following PCI, with 
3-5% having dispensings within 15 to 90-days. Thus, using the 14-day window, we 
identified most of the patients with evidence of initiation of study treatment following 
PCI. Most of the 27,049 excluded did not have claims for the therapies of interest. 
































































Page 7, lines 38-43:    The assigning of a random day in the month for each death seems odd. 
This reads as each death was given its own random day.  It would seem more prudent to just 
give all deaths the same day of the month, such as the 1st, 15th, or 30th.  This way is would be 
consistent for all deaths.
Response: We sincerely appreciate reviewer’s insightful comments. We considered the 
random date assignment a more suitable approach than using a same mid-month date. 
We also measured day of death using the first and last day of the month and this did not 
change the study results. 
Page 8, lines 22-24:    Why were patients switched to only clopidogrel censored? Anytime a 
patients was switched, the data for that drug should end.
Response: Patients that switched to ticagrelor or prasugrel were not censored. The risk-
time attributed to the ‘switched to’ agent was included in estimating the 
pseudopopulation consistent with the time-varying exposure methods described in the 
statistical analysis section. 
Page 8, line 42:        Not sure why COPD (or asthma in your table) are included. They are not 
risk factors for CVD or bleeding.
Response: These baseline covariates have been included in other observational studies 
for these therapies. 
Results: Please add the mean and median follow up times for each agent.
Response: Added to table 2.
Limitations:    It would seem that the third limitation on the counting of subsequent events could 
be fixed by matching additional codes with hospitalizations and not clinic visits.  As well 
requiring a primary code for ACS on subsequent admissions. This is actually critical to the 
internal validity of your data.
Response: From the reviewer’s comments, we removed this limitation. The outcomes 
were identified via validated algorithms cited in the text evaluating hospitalizations and 
not clinic visits.
References:     In Pharmacotherapy the journal names are not italicized and do not have a 
period after them.  DOI numbers are also not used by the journal.  Please be sure to review the 
instructions to authors before your submission. In references 3-5, 8, 9, 17, 18, 25, 28, and 29 all 
of the words in the title are capitalized, which is not appropriate for referencing. This 
inconsistency should have been caught by the lead or senior authors prior to submission.
Response: The references in the word document have no capitalizations. Perhaps this 
occurred during uploading or converting to PDF. I will check to be sure that this does not 
occur again.  
































































Table 2:        Please add the actual event rates to this table in addition to the HR and 95% CI. 
Also, the HR and 95% CI do not need to all be in separate columns.  This is awkward to read. 
They can all go in the same column.
Response: Added event rates to table 3. Reformatted the columns in table 4. 
Figure 2 and 3: Is it appropriate to label the y-axis “estimated probability of survival” when you 
are not evaluating survival.  Figure 2 is the composite ischemic endpoints and Figure 3 is major 
bleeding. May be better to label as “estimated probability event free survival”
Response: Updated axis titles. 
Reviewer: 3
Comments to the Author
Statistical and Methodological Review
This study uses contemporary pharmacoepidemiologic methods to overcome limitations of prior 
studies that have evaluated the comparative effectiveness and safety of prasugrel and 
ticagrelor. It has many strengths. I believe a few things need to be further discussed or specified 
and have some relatively minor concerns about other aspects of the methods.
Response: We sincerely appreciate the reviewer’s positive comments. We will address all 
your comments diligently. 
The time-period of the data is not entirely clear, and this is important because of the use of ICD-
9 codes to identify outcomes. The censoring criteria do not mention September 2015, the end of 
the study period, as a reason for censoring.
Response: Added Data end window in the ‘censoring’ section of methods. 
Please comment on validation studies and the performance characteristics of the outcome 
definitions, i.e. PPV. I’m not entirely sure why 412, old MI, was included in that definition. 436 
also is not a particularly valid code for stroke since guidance on stroke coding changed in the 
mid-2000s with instructions not to code strokes this way. The impact may be minimal since it is 
used less often, but using a study using recent data as a reference for its validity is important. It 







Response: We evaluated outcomes as described in the cited validation algorithms.
































































Please comment on the limitations of Social Security Death Index data for capturing mortality, 
and any validation studies vs. the National Death Index that may have been done in this data 
source. This data source has changed to no longer include state death data and sensitivity now 
appears to be limited. 
Response: The death file included within this dataset is the Social Security 
Administration Death Master file. Since 2013 it was no longer mandatory for states to 
report death events to the Social Security Administration. As such, death events are 
expected to be non-differentially underreported.7 This is added to the limitations with the 
citation.6
Why is angina being treated as a time-varying covariate? It seems to me that it’s likely on the 
causal pathway from drug choice to MI since the purpose of these drugs is to prevent ischemic 
events. It seems reasonable to include in the analysis of bleeding since it may lead to other 
drugs that increase bleeding risk, but it’s not clear to me why it would be considered a 
confounder with MI as an outcome.
Response: If a patient has an ACS, this will sometimes lead to a change in the agent 
used for DAPT (e.g. from prasugrel to ticagrelor). 
A sensitivity analysis using only primary position MI codes may be beneficial for dealing with the 
challenges of differentiating visits related to prior MI and new acute MI.
Response: We utilized a validated claims algorithm for outcomes. This included MI-
related hospitalization with length of stay >= 3days. Since we are not evaluating MI-
related outpatient claims we believe that there is minimal opportunity for misclassifying 
historical MI event for a new MI event. We have removed this language from the 
limitations section. 
The covariate list doesn’t seem optimal for bleeding events, as it lacks peptic ulcer disease, 
inflammatory bowel disease, and some other GI abnormalities that pose bleeding risk. PPI use 
may handle peptic ulcer disease to some extent, but many people without peptic ulcer disease 
take PPIs. I’m not sure this necessitates redoing all the analyses, but can you comment on why 
these weren’t included?
Response: We appreciate the reviewer’s important suggestion. We acknowledge that 
these suggestions would improve the analysis.    While many of the covariates were 
selected to mimic previous clinical trials, information regarding gastrointestinal 
disorders or abnormalities may be factors of interest.  
Please include an appendix that specifies the ICD codes used to define different covariates, as 
this is necessary for reproducibility of the work and assessment of the appropriateness of the 
methods.
Response: Thank you for your important suggestion. We have added an eTable that 
present all ICD codes to define the covariates. 

































































































































1. Alexandrescu, R., Bottle, A., Jarman, B. & Aylin, P. Current ICD10 codes are insufficient to clearly 
distinguish acute myocardial infarction type: a descriptive study. BMC Health Serv Res 13, 468 (2013).
2. Song, C. et al. Ninety-Day Readmission and Long-Term Mortality in Medicare Patients (≥65 Years) 
Treated With Ticagrelor Versus Prasugrel After Percutaneous Coronary Intervention (from the Blue 
Cross Blue Shield of Michigan Cardiovascular Consortium). Am. J. Cardiol. 120, 1926–1932 (2017).
3. Coons, J. C. et al. Comparative Effectiveness and Safety Analysis of Dual Antiplatelet Therapies Within 
an Integrated Delivery System. Ann Pharmacother 51, 649–655 (2017).
4. Yudi, M. B. et al. Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes 
undergoing percutaneous coronary intervention. Intern Med J 46, 559–565 (2016).
5. Alexopoulos, D. et al. Contemporary antiplatelet treatment in acute coronary syndrome patients 
undergoing percutaneous coronary intervention: 1-year outcomes from the GReek AntiPlatElet 
(GRAPE) Registry. J. Thromb. Haemost. 14, 1146–1154 (2016).
6. Kim, K. et al. Comparative Effectiveness of Oral Antiplatelet Agents in Patients with Acute Coronary 
Syndrome. Pharmacotherapy 37, 877–887 (2017).
7. Levin, M. A., Lin, H.-M., Prabhakar, G., McCormick, P. J. & Egorova, N. N. Alive or dead: Validity of the 
Social Security Administration Death Master File after 2011. Health Services Research 54, 24–33 
(2019).



















































































































































































Page 44 of 43
Pharmacotherapy submission
Pharmacotherapy submission
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
